CAS: 486-12-4 - Triprolidine
Fórmula:C19H22N2
InChI:InChI=1S/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11+
Clave InChI:InChIKey=CBEQULMOCCWAQT-WOJGMQOQSA-N
SMILES:N=1C=CC=CC1C(=CCN2CCCC2)C3=CC=C(C=C3)C
- Sinónimos:
- 2-[(1E)-1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]pyridine
- Pyridine, 2-[(1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]-
- Pyridine, 2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-, (E)-
- Pyridine, 2-[3-(1-pyrrolidinyl)-1-p-tolylpropenyl]-, (E)-
- Trans-1-(4'-methylphenyl)-1-(2''-pyridyl)-3-pyrrolidino-1-propene
- Tripolidina
- Triprolidin
- Triprolidine
- Tripyrolidine
- trans-1-(2-Pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene
- Ver más sinónimos
- trans-1-(4-Methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene
- trans-2-[3-(1-Pyrrolidinyl)-1-p-tolypropenyl]pyridine
- 2-[(1Z)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridine
- Pyridine, 2-[(1E)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-
- (E)-1-(2-pyridyl)-3-pyrrolidin-1-yl-1-p-tolylpropene
- 2-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridine hydrochloride
Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
---|---|---|---|---|
Triprolidine REF: TM-T60514CAS: 486-12-4 | - - - | 1.386,00 €~2.279,00 € | Mar 14 Ene 25 | |
Actidil REF: 3D-AAA48612CAS: 486-12-4 | Min. 95% | A consultar | Mar 18 Feb 25 |
Triprolidine
CAS:486-12-4
Triprolidine: oral H1 receptor blocker with motor/sensory spinal effects, for allergy research.
Fórmula:
C19H22N2
Forma y color:
Liquid
Peso molecular:
278.39
Ref: TM-T60514
25mg | 1.386,00 € | ||
50mg | 1.805,00 € | ||
100mg | 2.279,00 € |
Entrega estimada en Estados Unidos, el Martes 14 de Enero de 2025
Actidil
CAS:486-12-4
Actidil is a drug that inhibits histamine release from mast cells and basophils, which are …
Fórmula:
C19H22N2
Pureza:
Min. 95%
Peso molecular:
278.4 g/mol
Ref: 3D-AAA48612
50mg | 196,00 € | ||
500mg | 737,00 € |
Entrega estimada en Estados Unidos, el Martes 18 de Febrero de 2025